An immunosuppressed rat model of Pneumocystis carinii pneumonia is described that utilizes simple, noninvasive intratracheal (i.t.) inoculation of cryopreserved parasites and results in development of severe P. carinii pneumonia within 5 weeks. This is an improvement over the most commonly used models of P. carinii pneumonia that rely on immune suppression to activate latent P. carinii infections and that often require 8 to 12 weeks to produce heavy infections of P. carinii. It is also less labor intensive than more recent models requiring surgical instillation of parasites. Our report describes a series of preliminary studies to select an appropriate strain of rat; to determine suitable methods for inducing uniform immunosuppression, P. carinii inoculation, and laboratory maintenance of P. carinii; and to determine effective animal husbandry methods for maintaining animals free from serious secondary infections. Results of our more detailed studies demonstrate that animals receiving two or three i.t. inoculations of approximately 106 cryopreserved P. carinii organisms have a predictable course of disease progression which includes moderate P. carinii infections within 3 weeks, severe P. carinii pneumonia in 5 weeks, and a high percentage of mortality due to P. carinii pneumonia in 6 weeks. Parasites were distributed evenly between the right and left lungs, regardless of the number of P. carinii inoculations administered. Non-P. carinii-inoculated immunosuppressed control rats maintained in microisolator cages remained free ofP. carinii, thus providing an important control that is missing from many P. carinii pneumonia models. Most non-P. carinii-inoculated control animals and P. carinii-inoculated rats treated with trimethoprim-sulfamethoxazole that were housed in open caging in the same room containing heavily infected animals had no detectable infections after 5 to 6 weeks of immunosuppression; however, some had a small number of P. carinii in their lungs. Because heavy, reproducible infections are achieved 5 weeks after i.t. inoculation, because few animals are lost to secondary infections, and because animals can be maintained as noninfected contemporaneous controls, this animal model is useful for the maintenance of P. carinii strains, for studies of the transmission and natural history of P. carinii, for the production of large numbers of organisms for laboratory studies, and for the evaluation of potential anti-P. carinii drugs.
Pneumocystis carinii pneumonia is a leading cause of morbidity and mortality in persons with AIDS. Historically, it has been the initial disease manifestation in more than 60% and ultimately occurred in at least 85% of AIDS patients in North America (4, 13) . P. caninii pneumonia is fatal in 5 to 10% of initial episodes and has been the cause of death in approximately 25% of AIDS patients reported in autopsy series (13) . Although recent, widespread implementation of prophylaxis for P. carinii pneumonia has apparently been successful in lowering its incidence, it remains an important disease; more deaths presently occur in the United States from P. carinii pneumonia than from all reportable diseases (8) . Thus, a major goal for biomedical research is increased success in diagnosis, prevention, and treatment of P. carinji pneumonia. To meet these goals, researchers must have access to reliable animal models of P. cannii pneumonia that can be used as a source of large numbers of organisms for laboratory studies and as a tool for evaluating the efficacy of new drugs.
Historically, most animal models used to study P. cannii relied on steroid-induced immunosuppression to activate latent P. carnii infections (1, 3, 6, 9-11, 14, 17, 18) . The presence of latent P. carinii infections in many breeding colonies of Sprague-Dawley rats resulted in this rodent becoming the animal of choice for most investigators (1, 3, (9) (10) (11) 17) . The utility of this animal model is often limited by * Corresponding author.
unknown baselines of P. carinii infection, the long time required for development of heavy infections (8 to 12 weeks), the lack of control over parasite strains, and often the presence of secondary infections that render many of the animals unusable. This animal model is becoming more difficult to maintain in most laboratories because of the reduced availability of rodents with latent P. cainni. Most suppliers have eliminated or are in the process of eliminating primary and opportunistic pathogens, including P. carinii, from commercial production colonies.
To circumvent many of the problems associated with the conventional (dirty rat) model of P. carinii pneumonia, investigators have developed surgical procedures to introduce P. carinii into the lungs of virus-free, P. carinii-free rats (2) . Although the surgical procedures are labor intensive, they provide a means of obtaining consistent, heavy P. carinii infection in immunosuppressed rats. In this communication, we describe the development of an improved animal model of laboratory-induced P. carinii infections that results in severe P. carinii pneumonia within 5 weeks after noninvasive intratracheal (i.t.) inoculation of parasites. This model produces consistent, heavy infections of P. carinii with minimal secondary bacterial infections and has been used extensively in our laboratory to evaluate candidate drugs for anti-P. carinii pneumonia activity and for propagation of a strain of P. carinii for laboratory studies.
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MATERIALS AND METHODS
Preliminary studies. A series of preliminary studies were conducted to select an appropriate strain of rat; to determine suitable methods of immunosuppression, P. carinii inoculation, and maintenance of P. carinii; and to determine effective animal husbandry methods for maintaining animals free from serious secondary bacterial infections. These studies are summarized below before a presentation of the materials and methods used in the more-detailed studies to develop the animal model.
(i) Selection of rat strain. Three strains of rats, SpragueDawley, Fisher 344, and Lewis, were evaluated and compared to determine which was best suited for steroid-induced immunosuppression and maintenance of P. cainni pneumonia. All 20 rats in each of the three strains developed heavy P. caninii infections 6 weeks after immunosuppression and i.t. inoculation of parasites; however, the inbred, virus-free Lewis rats developed fewer secondary bacterial infections and were more docile. Female Lewis rats (Harlan SpragueDawley, Inc., Indianapolis, Ind.) weighing 120 to 140 g were utilized in all subsequent studies to develop the model.
(ii) Immunosuppression regimen. Two immunosuppressive therapies were compared. Depo-Medrol (methlyprednisolone acetate; The Upjohn Co., Kalamazoo, Mich.; 40 and 30 pug/g for weeks 1 and 2, continuing weekly at 20 ,ug/g) administered subcutaneously resulted in a more controlled, uniform dose of immunosuppression than did dexamethasone (Schering Corp., Kenilworth, N.J.) administered in the drinking water. Animals immunosuppressed with methylprednisolone acetate developed heavy, consistent P. cannii infections within 6 weeks following i.t. inoculation of parasites.
(iii) Preparation and maintenance of P. carinii inoculum. Parasite inoculum was prepared from the lungs of heavily infected donor rats housed in microisolator cages (Lab Products Inc., Maywood, N.J.; cage bottom no. 18727; stainless steel wire lid no. 10428; and filter top no. 18704). Rats were anesthetized with approximately 135 ,ug of ketamine (ketamine hydrochloride injection USP, 100 mg/ml; Aveco Co., Inc., Fort Dodge, Iowa) per g and 4 ,ug of xylazine (20 mg/ml; Mobay Corp., Shawnee, Kans.) per g, and the thoracic and abdominal cavities were aseptically opened. After the abdominal aorta and vena cava were severed, the pulmonary circulation was aseptically perfused by using a 10-cm3 syringe and 23-gauge needle to inject approximately 7 ml of 4°C Alsever's solution (GIBCO Laboratories, Grand Island, N.Y.) into the pulmonary artery. Perfused lungs were collected, suspended in 1:40 (wt/vol) Dulbecco modified Eagle medium supplemented with 10% fetal calf serum, glutamine (2 mM), pyruvate (1 mM), penicillin-streptomycin (100 U/100 ,ug/ml), and amphotericin B (Fungizone; 0.1 ,ug/ml) (S-DMEM), and homogenized (Brinkman Polytron homogenizer, speed 5 for 10 to 15 s). Trophozoites, precysts, and cysts of P. carinii were separated from most of the host cell debris by two repetitions of centrifugation at 40 x g and 1,000 x g for 10 min. The supernatant was saved from the 40 x g centrifugation, whereas the pellet was saved from the 1,000 x g centrifugation. The final P. carinii-enriched pellet was resuspended in S-DMEM, counted with a hemacytometer, resuspended at approximately 2 x 107 P. carinii organisms per ml in S-DMEM containing 7.5% (vol/vol) dimethyl sulfoxide, cryopreserved by using a 1°C/min cooling cycle (model 700 automated cell freezer; Cryo-Med, Division of Forma Scientific Inc., New Baltimore, Mich.), and stored as 1-ml aliquots in liquid nitrogen for up to examined by using a final magnification of x 1,000 and x 400, respectively. All slides were randomized and then examined microscopically by two persons using a blinded protocol. In rare cases in which infection scores of the two observers differed by more than 0.5, the slides were reevaluated and the actual infection score was determined.
During the study to investigate the kinetics of P. carinii infection following i.t. inoculation (see below), another procedure was evaluated to determine the severity of P. carinii infections in the lung. Infection scores obtained from microscopic examination of Giemsa-and methenamine silver-stained impression smears were compared with infection scores obtained from methenamine silver-stained lung homogenates, the new evaluation procedure. Stained slides of lung homogenates were prepared at the time of necropsy and were scored by the same criteria described above for methenamine silver-stained impression smears. Rats were anesthetized with ketamine-xylazine (as described above), exsanguinated via the right atrium to remove excess blood from the pulmonary circulation, and then necropsied. The lungs were removed from each rat, weighed, and then homogenized in a 40x (wt/vol) volume of sterile water for approximately 15 s (Brinkman Polytron homogenizer, setting 5). Large particulates comprising host cell debris were allowed to settle for approximately 10 min, and then 4-,ul samples of the supematant containing P. cannii cysts were distributed evenly onto the wells of Teflon-coated, 12-well microscope slides (catalog no. 99910090; 6-mm well diameter; Shandon Inc., Pittsburgh, Pa.) and stained with methenamine silver. Infection scores from lung homogenates diluted 1:40 in water (wt/vol) were slightly lower but comparable to those of Giemsa-and methenamine silverstained lung impression smears (see Tables 2 and 3 ).
Optimizing i.t. inoculation of P. carinii. Immunosuppressed rats were given one, two, or three i.t. inoculations of parasites (0.1 ml of S-DMEM containing 106 P. carinii parasites administered 48 h apart) to determine the optimum number of inoculations required to produce consistent, heavy P. carinii infections. To reduce the number of animals used, these rats also served as P. carinii-infected controls for therapy studies to evaluate candidate drugs for anti-P. caninii pneumonia activity. Noninfected nosuppressed rats housed in standard wire-bottom cages in carinii-infected animals housed in wire-bottom cages in the the same room as heavily infected animals had small numsame room when these animals were placed in a cage rack bers ofP. carinii in their lungs after 6 weeks ( Fig. 1 ; Table 1 ), without P. carinii-infected animals.
the remaining animals (approximately 85%) maintained in Kinetics of the P. carinii infection. Mean P. carinii infection microisolator cages remained free of detectable P. carinii.
scores and infection score incidence at different times after
Housing non-P. carinii-inoculated, immunosuppressed rats i.t. inoculation of P. carinii are presented in Tables 3 and 4, in the same cage rack as heavily infected animals resulted in respectively. P. carinii infections were well established in all a higher incidence of moderate P. carinii infection compared groups by 3 weeks, regardless of the number of inoculations with noninoculated controls housed in a separate cage rack received, and mean infection scores at this time ranged from (Table 1 , study 3). Mean P. carinii infection scores deter-3.87 to 4.04 (Table 3) . P. carinii pneumonia progressed mined by evaluation of stained lung impression smears were consistently over time for each of the inoculation groups, comparable for both Giemsa and methenamine silver stains and by week 5, mean infection scores of all animals receiving for each of the animals evaluated ( Fig. 1; Table 1 ).
two or three P. carinii inoculations were 4.97 or greater. The Distribution of P. carinii in lungs following i.t. inoculation.
severity of P. carinii pneumonia at 6 weeks was directly Parasites were distributed evenly between the left and right related to the number of inoculations received; however, lungs regardless of the number of P. carinii inoculations high mortality rates resulting from heavy P. carinii pneumoadministered (Table 2 ). Animals receiving two or three P.
nia during weeks 5 and 6 p.i. reduced the number of animals carinii inoculations had higher mortality rates and more available for evaluation. consistent, heavy mean P. carinii infections than rats receiv-
The 5-week P. carinii pneumonia model for drug screening. ing one P. carinii inoculation. All mortalities were attributed Infection scores obtained from P. carinii-infected control to heavy P. carinii burdens. In addition, little or no evidence animals, non-P. carinii-infected control animals, and P. of P. carinii pneumonia was found in the lungs of non-P.
carinii-infected TMP-SMX-treated animals from 10 studies 2.0-2. are presented in Fig. 2 and Table 5 .
DISCUSSION
The most widely used animal model of P. cannii pneumonia, first developed by Frenkel et al. (6) , relies on activation of latent P. cannii infections in rats immunosuppressed by steroids. The presence of latent P. cannii infections in most breeding colonies of Sprague-Dawley rats resulted in this rodent becoming the animal of choice for most investigators (1, 3, 9, 10, 17). These rats have been used both as a source of organisms for laboratory studies and for most evaluations of drugs for efficacy against P. carinii pneumonia (1, 3, 9, 10, 12, 14, 17) . Inherent to this model are the problems of inconsistent infections, the long course (8 to 12 weeks) of immunosuppression to allow development of heavy infections, a lack of control over P. cainni strains that may be present, and often a high incidence of secondary infections that render many of the animals unusable (1, 3, 16 ). These problems are thought to be primarily a result of variations among rats in the degree of latent infections, in the amount of steroids consumed or their susceptibility to steroids, and in the presence of opportunistic pathogens that may cause disease when the animals are immunosuppressed (1). Another aspect that has recently made this animal model increasingly difficult for many researchers is a marked reduction in the supply of rats with latent P. cannii infections. Through continuous upgrading of the pathogen-free status of most breeding stocks, animal suppliers have succeeded in reducing or eliminating inherent P. carinii infections in their laboratory animal colonies. Today, many of the commercial rodent colonies are free of viral and bacterial pathogens and do not have latent P. cannii. In the absence of substantial monetary incentives to maintain rat colonies that have latent P. caninii, it is likely that the traditional dirty rat model may soon be unavailable to many researchers.
A logical way to circumvent many of the problems associated with the conventional model described above is to induce controlled laboratory infections in P. carinii-free animals. Early attempts to induce laboratory infections met with varied success. Walzer et al. (19) successfully infected nude mice by percutaneous injection of the parasites into the lung. Although intranasal inoculation of the organism was used successfully to produce P. cannii pneumonia in mice in incisors. bImmunosuppressed rats inoculated twice with P. carinii (P. carnii-infected control rats).
c Non-P. carinii-inoculated immunosuppressed control rats housed for 5 weeks in open cages in the same room as but away from heavily infected animals. In study 4 , these rats were housed in open caging near heavily infected animals. one laboratory (7), the technique did not produce P. carinii pneumonia in animal models used in two other laboratories (6, 19) . More recently, a rat model was developed in which consistent laboratory-induced P. carinii infections were achieved and which eliminated some of the undesirable variables associated with activation of latent P. carinii infections (2) . However, labor-intensive surgical manipulation was required to inoculate the organisms into the trachea.
Our animal model of laboratory-induced P. carinii pneumonia represents an improvement over the existing models. The key features that make the model useful for a variety of studies include the use of relatively non-labor-intensive, controlled, uniform immunosuppression of P. carinii-free animals; the use of rapid, noninvasive i. Table 5 , only four deaths were attributed to causes other than P. cafinii pneumonia; two died from steroid-induced streptococcal nephritis and two died of malnutrition attributed to malocclusion of the front incisors. Although kidney lesions due to steroidinduced streptococcal nephritis were occasionally observed at necropsy, less than 1% of the immunosuppressed animals apparently died from this cause. The virus-free status of Lewis rats used in our studies, the shorter duration of immunosuppression, and the animal housing and care procedures outlined above resulted in a lower occurrence of serious secondary bacterial infections compared with most models of P. carinii pneumonia; however, complete suppression of localized bacterial infections was not achieved.
Tracheal intubation with a standard 20-gauge feeding tube provides a rapid method of inoculating parasites deep into the lung without surgical manipulation, visualization of the epiglottis, or special equipment. Placement of the feeding tube i.t. is easily verified, and rats recover from light halothane anesthesia within minutes. After becoming familiar with the technique, one person can inoculate P. carindi into the lungs of 100 to 120 rats in 1 h.
The use of cryopreserved parasites along with i.t. inoculation of P. carinii-free rats provides a practical means of long-term maintenance of individual P. carinii isolates or strains and a consistent source of large numbers of parasites for laboratory studies. By maintaining a small stock colony of i.t.-inoculated animals in microisolator cages, one can be assured that heavily infected animals are available for laboratory use when needed. Inoculation of five rats i.t. each week should provide an uninterrupted, adequate supply of P. carinii for most laboratory studies.
A major shortcoming of the conventional model of P. carinii pneumonia that is overcome by our model is the absence of immunosuppressed, non-P. carinii-infected control animals. By using P. carinii-free rats housed in microisolators, immunosuppressed, noninfected animals can be incorporated into a variety of studies that require the presence of this type of contemporaneous control to properly interpret the data obtained.
Perhaps the most important feature of our model is the predictable course of disease progression that results in most, if not all, rats having moderate infections 2 and 3 weeks after i.t. inoculation of P. cannii, severe P. carinii pneumonia 4 and 5 weeks p.i., and approximately 50% mortality due to P. carinii pneumonia at 6 weeks p.i. This is preferable to the long (8 to 12 weeks), often unpredictable course of infection that occurs in conventional dirty rat models. In the early stages of our model development, rats were necropsied at 6 weeks p.i.; however, in later studies, more than 50% of P. carinii-infected control rats died of severe P. caninii pneumonia by 6 weeks p.i. Therefore, a 5-week study duration was selected to optimize percent survival among heavily infected rats used to evaluate experimental compounds for both therapeutic and prophylactic activity against P. cannii pneumonia. The therapeutic evaluation model allows 2 weeks for moderate P. cannii infections to develop and then 3 weeks to evaluate the efficacy of experimental compounds. The use of P. carinii-free rats and coordination of parasite inoculation and initiation of therapy within a 24-h period allows a more-controlled evaluation of prophylactic activity compared with conventional models that rely on activation of latent P. cannii infections.
In summary, we describe an immunosuppressed rat model of P. carinii pneumonia that results in a predictable course of disease development which includes moderate P. carinii infections in 2 to 3 weeks, heavy infections in 4 to 5 weeks, and a high percentage of mortality due to P. cannii pneumonia in 6 weeks. The model also provides uninfected, immunosuppressed contemporaneous controls, an experimental compartment that is needed to correctly interpret results obtained from many different studies. Noninvasive i.t. inoculations of cryopreserved parasites into P. carinii-and virus-free rats immunosuppressed by weekly injections of methylprednisolone are key features of the model that result in the development of consistent heavy P. carinii infections and very few secondary infections that can interfere with studies. This model is useful for maintaining over time isolates or strains of P. cannii, for producing large numbers of parasites for laboratory studies, and for evaluating the anti-P. carinii activity of experimental compounds and approved drugs.
